Prothrombin

Common Name(s)

Prothrombin

Description for this condition is not yet available.
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Prothrombin" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
Top

How do you compare to others with this condition?

Privately answer questions about your health. Let resources, you select, come to you.

Anonymously share and see how your answers compare with others with this condition while privately providing key pieces of information to medical researchers, disease advocacy groups, and others ONLY YOU select to help speed up cures and better alternatives.

 
 

Advocacy and Support Organizations

 

Condition Specific Organizations

Following organizations serve the condition "Prothrombin" for support, advocacy or research.

There are currently no organizations listed in Disease InfoSearch that support this condition. Create a listing.

 

 

General Support Organizations

Not finding the support you need? Show General Support Organizations

 
 
 
 
Top

Scientific Literature

Articles from the PubMed Database

Research articles describe the outcome of a single study. They are the published results of original research.
The terms "Prothrombin" returned 850 free, full-text research articles on human participants. First 3 results:

Dose-dependent effect of daptomycin on the artificial prolongation of prothrombin time in coagulation abnormalities: in vitro verification.
 

Author(s): Hideki Hashimoto, Makoto Saito, Naoki Kanda, Takehito Yamamoto, Makiko Mieno, Shuji Hatakeyama

Journal:

 

Several studies have reported that daptomycin induced artificial prolongation of prothrombin time (PT) in some test reagents, particularly in warfarin users. However, it remains unknown whether the artificial prolongation can be affected by coagulation abnormalities other than the ...

Last Updated: 31 Dec 1969

Go To URL
The effects of hemolysis on plasma prothrombin time and activated partial thromboplastin time tests using photo-optical method.
 

Author(s): Yetti Hernaningsih, Jeine Stela Akualing

Journal: Medicine (Baltimore). 2017 Sep;96(38):e7976.

 

Hemolysis is the most common reason why coagulation test samples are rejected. However, the effects of hemolysis on plasma prothrombin time (PPT) and activated partial thromboplastin time (APTT) are rarely investigated and the results are controversial. This research aims to analyze ...

Last Updated: 31 Dec 1969

Go To URL
Theoretical Modeling of Coagulation Management With Therapeutic Plasma or Prothrombin Complex Concentrate.
 

Author(s): Herbert Schöchl, Oliver Grottke, Ken Sutor, Kieron Dony, Martin Schreiber, Marco Ranucci, Peter W Collins

Journal: Anesth. Analg.. 2017 11;125(5):1471-1474.

 

Prothrombin complex concentrates (PCCs) have been associated with a possible risk of thromboembolic complications, potentially attributable to an increased ratio of the plasma concentration of factor II (FII) to antithrombin (AT). We developed a mathematical model to examine the relationship ...

Last Updated: 31 Dec 1969

Go To URL

Reviews from the PubMed Database

Review articles summarize what is currently known about a disease. They discuss research previously published by others.
The terms "Prothrombin" returned 45 free, full-text review articles on human participants. First 3 results:

Prothrombin Complex Concentrate for Vitamin K Antagonist-Associated Intracranial Hemorrhage - Global Evidence and the Japanese Perspective.
 

Author(s): Masahiro Yasaka, Andres Brainsky, Kazunori Toyoda

Journal: Circ. J.. 2017 Oct;81(11):1564-1573.

 

Patients receiving vitamin K antagonists (VKAs) are at increased risk of bleeding. Intracranial hemorrhage (ICH) is a major cause of morbidity and mortality in this population, and is a particular concern among Japanese clinicians, given reports of an elevated risk of this bleeding ...

Last Updated: 31 Dec 1969

Go To URL
Benefits and harms of 4-factor prothrombin complex concentrate for reversal of vitamin K antagonist associated bleeding: a systematic review and meta-analysis.
 

Author(s): Marjolein P A Brekelmans, Kim van Ginkel, Joost G Daams, Barbara A Hutten, Saskia Middeldorp, Michiel Coppens

Journal: J. Thromb. Thrombolysis. 2017 Jul;44(1):118-129.

 

Prothrombin complex concentrate (PCC) is used for reversal of vitamin K antagonists (VKA) in patients with bleeding complications. This study aims to assess benefits and harms of 4-factor PCC compared to fresh frozen plasma (FFP) or no treatment in VKA associated bleeding. PubMed, ...

Last Updated: 31 Dec 1969

Go To URL
Why is it so difficult to show that prothrombin complex concentrates are superior to fresh-frozen plasma for warfarin reversal?
 

Author(s): Giorgia Saccullo, Alexandra M Bucko, Joost J Van Veen, Michael Makris

Journal: Blood Transfus. 2017 05;15(3):277-278.

 

Last Updated: 31 Dec 1969

Go To URL
 
 
Top

Clinical Trial Information This information is provided by ClinicalTrials.gov

Fixed Versus Variable Dosing of 4-factor Prothrombin Complex Concentrate for Emergent Warfarin Reversal
 

Status: Recruiting

Condition Summary: Acute Bleeding on Long-Term Anticoagulation Therapy; Hemorrhage; Significant Bleeding in Patients With a Coagulopathy (Prolonged Thrombin Time); Urgent Reversal of Vitamin K Antagonist (VKA) Anticoagulation

 

Last Updated: 5 Jun 2018

Go to URL
Point-of-care Assessment of Thrombin Generation and Platelet Function in Children Requiring Cardiopulmonary Bypass
 

Status: Not yet recruiting

Condition Summary: Platelet Function Tests; Thrombin Generation Tests; Perioperative Coagulopathy

 

Last Updated: 8 May 2018

Go to URL
The Role of Prothrombin Gene Polymorphism as a Risk Factor for Recurrent Pregnancy Loss
 

Status: Not yet recruiting

Condition Summary: Recurrent Pregnancy Loss

 

Last Updated: 3 Jul 2017

Go to URL